Erste Asset Management Gmb H Mirati Therapeutics, Inc. Transaction History

Erste Asset Management Gmb H

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Nov 26, 2024	SELL	$0.0 - $59.28 $0 - $1.49 Million	-25,200 Closed	0 $0
Q3 2022 Nov 26, 2024	BUY	$59.5 - $86.7 $1.5 Million - $2.18 Million	25,200 New	25,200 $1.76 Billion
Q2 2022 Nov 26, 2024	BUY	$39.16 - $88.71 $986,831 - $2.24 Million	25,200 New	25,200 $1.69 Billion
Q4 2021 Nov 22, 2024	BUY	$132.01 - $190.29 $3.33 Million - $4.8 Million	25,200 New	25,200 $3.63 Billion
Q3 2021 Nov 22, 2024	BUY	$132.13 - $177.45 $1.59 Million - $2.13 Million	12,000 Added 90.91%	25,200 $4.39 Billion
Q4 2020 Nov 22, 2024	SELL	$162.05 - $240.27 $16,205 - $24,027	-100 Reduced 0.75%	13,200 $2.92 Billion
Q3 2020 Nov 22, 2024	BUY	$113.26 - $167.27 $1.51 Million - $2.22 Million	13,300 New	13,300 $2.21 Billion
Q4 2019 Nov 22, 2024	BUY	$70.76 - $128.86 $778,360 - $1.42 Million	11,000 New	11,000 $1.41 Billion
Q1 2019 Nov 22, 2024	BUY	$43.65 - $78.95 $480,150 - $868,450	11,000 New	11,000 $812 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Erste Asset Management Gmb H, based on Form 13F filings with the SEC.

Stay updated on Erste Asset Management Gmb H with notifications on news.